Discussion on the indications and timing of targeted therapy and immunotherapy before and after liver transplantation for hepatocellular carcinoma
10.3969/j.issn.1674-7445.2022.05.003
- VernacularTitle:肝癌肝移植手术前后靶向及免疫治疗的指征及时机探讨
- Author:
Keyue LI
1
;
Guowei WEI
;
Tao LI
;
Chunlin WANG
;
Keli TANG
;
Yi ZHANG
;
Yan LIU
Author Information
1. Department of Hepatobiliary Surgery, Guizhou Provincial People's Hospital, Guiyang 550002, China
- Publication Type:Research Article
- Keywords:
Hepatocellular carcinoma;
Liver transplantation;
Targeted therapy;
Immunotherapy;
Antiangiogenic targeted drug (AATD);
Immune checkpoint inhibitor (ICI);
Transcatheter arterial chemoembolization (TACE);
Stereotactic radiotherapy;
Radiofrequency ablation
- From:
Organ Transplantation
2022;13(5):561-
- CountryChina
- Language:Chinese
-
Abstract:
Liver transplantation is one of the main treatments of early hepatocellular carcinoma (HCC). The recurrence of HCC after liver transplantation severely affects the long-term survival rate of the recipients. Targeted therapy and immunotherapy play a critical role in HCC downstaging, preventing disease progression, reducing recurrence rate, prolonging the survival and improving the quality of life. However, no consensus has been reached on the application of targeted therapy and immunotherapy in recipients undergoing liver transplantation for HCC, including indications, timing and dosage. In this article, clinical research progresses on the indications and timing of targeted therapy and immunotherapy before and after liver transplantation for HCC were reviewed, aiming to provide reference for prolonging the survival of recipients after liver transplantation for HCC.
